{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:36:54Z","timestamp":1787773014582,"version":"build-2784847793"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>Circulating free DNA (cfDNA) analysis has emerged as novel noninvasive diagnostic biomarker in several solid tumors. Raised levels have been reported in several malignancies and may correlate with clinicopathological and treatment response. The current study was designed to assess the diagnostics of cfDNA in different tumor types of malignancies correlating with tumor (T), nodes (N), and metastases (M) stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Serum samples were collected from treatment na\u00efve cases with histologically diagnosed tumors including 23 brain tumors, 48 breasts, 50 gallbladder carcinoma (GBC), 13 lungs, 68 oral squamous cell carcinoma (OSCC), and 25 normal controls. CfDNA was quantified with real-time polymerase chain reaction (PCR), Invasive ductal carcinoma (IDC) using beta-globin gene amplification. Cut off values for diagnostics were calculated using receiver operating curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Contrary to other cfDNA studies where it was postulated that cfDNA would not cross the blood\u2013brain barrier and reach the systemic circulation, we found detectable cfDNA in glioma with median (Q1\u2013Q3) of 349.22 ng\/ml (19.87\u20131276.58). Median cfDNA concentration in breast, gallbladder, lung, oral and normal controls was 328.72 (128.38\u2013624.44), 778.50 (589.88\u20131864.35), 348.73 (194.67\u2013483.61), 386.27 (47.88\u2013959.67), and 74.12 (49.66\u2013120.00), respectively. Grades I and II glioma had significantly lower levels compared to Grades III and IV (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0001). Significant difference in median cfDNA values in IDC and GBC was observed with increasing tumor grades, stage, T stage, nodal stage and metastasis and with stage of OSCC cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>CfDNA levels showed good diagnostic discrimination in glioma, GBC, breast, lung carcinoma, and OSCC. Significant increase in titers was evident with increase in cancer stage from I to IV in breast, GBC and OSCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpm.ijpm_474_20","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T15:49:39Z","timestamp":1724946579000},"page":"93-99","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of circulating DNA in malignant neoplasia from diverse locations"],"prefix":"10.4103","volume":"65","author":[{"given":"Swati","family":"Kumari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuzhat","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tripti","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Kaif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhup","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav Arun","family":"Sonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20240829","first-page":"3213","article-title":"Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"Clin Oncol"},{"key":"R2-16-20240829","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2010.28.7045","article-title":"Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer","volume":"29","author":"Krebs","year":"2001","journal-title":"J Clin Oncol"},{"key":"R3-16-20240829","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.bbagen.2007.01.017","article-title":"Biomarkers for early detection of breast cancer: What, when, and where?","volume":"1770","author":"Levenson","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"R4-16-20240829","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrc1041","article-title":"The case for early detection","volume":"3","author":"Etzioni","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"R6-16-20240829","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.mrrev.2006.11.002","article-title":"Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance","volume":"635","author":"Gormally","year":"2007","journal-title":"Mutat Res"},{"key":"R7-16-20240829","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1196\/annals.1448.012","article-title":"Clinical relevance of circulating nucleosomes in cancer","volume":"1137","author":"Holdenrieder","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"R8-16-20240829","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1196\/annals.1448.027","article-title":"Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps","volume":"1137","author":"Su","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"R9-16-20240829","doi-asserted-by":"crossref","first-page":"16368","DOI":"10.1073\/pnas.0507904102","article-title":"Detection and quantification of mutations in the plasma of patients with colorectal tumors","volume":"102","author":"Diehl","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-16-20240829","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0009-8981(01)00665-9","article-title":"About the possible origin and mechanism of circulating DNA: Apoptosis and active DNA release","volume":"313","author":"Stroun","year":"2001","journal-title":"Clin Chim Acta"},{"key":"R11-16-20240829","first-page":"4675","article-title":"Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients","volume":"61","author":"Sozzi","year":"2001","journal-title":"Cancer Res"},{"key":"R12-16-20240829","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/sj.bjc.6601609","article-title":"Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR","volume":"90","author":"Gal","year":"2004","journal-title":"Br J Cancer"},{"key":"R13-16-20240829","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.juro.2007.08.091","article-title":"Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer","volume":"179","author":"Ellinger","year":"2008","journal-title":"J Urol"},{"key":"R14-16-20240829","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1309\/DBPX1MFNDDJBW1FL","article-title":"Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer","volume":"129","author":"Altimari","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"R15-16-20240829","first-page":"2747","article-title":"Quantification of plasma cell-free DNA in patients with gastric cancer","volume":"27","author":"Sai","year":"2007","journal-title":"Anticancer Res"},{"key":"R16-16-20240829","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1373\/clinchem.2006.068577","article-title":"Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: Direct quantitative PCR for ALU repeats","volume":"52","author":"Umetani","year":"2006","journal-title":"Clin Chem"},{"key":"R17-16-20240829","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/ijc.11003","article-title":"Circulating nucleosomes and response to chemotherapy: An in vitro, in vivo and clinical study on cervical cancer patients","volume":"104","author":"Trejo Becerril","year":"2003","journal-title":"Int J Cancer"},{"key":"R18-16-20240829","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/jnci\/94.22.1697","article-title":"Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer","volume":"94","author":"Chang","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R19-16-20240829","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.juro.2008.08.118","article-title":"Cell-free circulating DNA: Diagnostic value in patients with testicular germ cell cancer","volume":"181","author":"Ellinger","year":"2009","journal-title":"J Urol"},{"key":"R20-16-20240829","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.3748\/wjg.v19.i20.3143","article-title":"Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma","volume":"19","author":"Chen","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R21-16-20240829","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12253-016-0087-0","article-title":"Quantification of circulating free DNA as a diagnostic marker in gall bladder cancer","volume":"23","author":"Kumari","year":"2017","journal-title":"Pathol Oncol Res"},{"key":"R22-16-20240829","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.febslet.2007.01.051","article-title":"Circulating (cell-free) nucleic acids\u2013A promising, non-invasive tool for early detection of several human diseases","volume":"581","author":"Swarup","year":"2007","journal-title":"FEBS Lett"},{"key":"R23-16-20240829","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinbiochem.2009.08.027","article-title":"Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?","volume":"43","author":"Van der Vaart","year":"2010","journal-title":"Clin Biochem"},{"key":"R24-16-20240829","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/1097-0142(19830601)51:11<2116::AID-CNCR2820511127>3.0.CO;2-S","article-title":"Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease","volume":"51","author":"Shapiro","year":"1983","journal-title":"Cancer"},{"key":"R25-16-20240829","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0009-8981(01)00666-0","article-title":"Circulating nucleic acids in plasma or serum","volume":"313","author":"Anker","year":"2001","journal-title":"Clin Chim Acta"},{"key":"R26-16-20240829","doi-asserted-by":"crossref","first-page":"111","DOI":"10.21037\/jgo.2017.10.02","article-title":"Investigation of targetable predictive and prognostic markers in gallbladder carcinoma","volume":"9","author":"Neyaz","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"R27-16-20240829","doi-asserted-by":"crossref","first-page":"98590","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"R28-16-20240829","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0009-8981(02)00091-8","article-title":"Cell-free DNA: Measurement in various carcinomas and establishment of normal reference range","volume":"321","author":"Wu","year":"2002","journal-title":"Clin Chim Acta"},{"key":"R29-16-20240829","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res"},{"key":"R30-16-20240829","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1373\/clinchem.2006.070417","article-title":"Cell-free plasma DNA as a novel marker of aseptic inflammation severity related to exercise overtraining","volume":"52","author":"Fatouros","year":"2006","journal-title":"Clin Chem"},{"key":"R31-16-20240829","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/clinchem\/46.3.319","article-title":"Plasma DNA as a prognostic marker in trauma patients","volume":"46","author":"Lo","year":"2000","journal-title":"Clin Chem"},{"key":"R32-16-20240829","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000213536","article-title":"Plasma DNA as cell death marker in elderly patients","volume":"39","author":"Fourni\u00e9","year":"1993","journal-title":"Gerontology"},{"key":"R33-16-20240829","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s12253-017-0380-6","article-title":"Diagnostic value of circulating free DNA integrity and global methylation status in gall bladder carcinoma","volume":"25","author":"Kumari","year":"2019","journal-title":"Pathol Oncol Res"},{"key":"R34-16-20240829","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4161\/cbt.4.2.1508","article-title":"Overview of cell death signaling pathways","volume":"4","author":"Jin","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"R35-16-20240829","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1155\/2005\/218759","article-title":"Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias","volume":"21","author":"Goebel","year":"2005","journal-title":"Dis Markers"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJPM.IJPM_474_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:16:40Z","timestamp":1787771800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJPM.IJPM_474_20"}},"subtitle":["Investigating a diagnostic role"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_474_20","relation":{},"ISSN":["0377-4929"],"issn-type":[{"value":"0377-4929","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}